23:41 , Apr 19, 2019 |  BioCentury  |  Product Development

Companies poised to take Chinese checkpoints global

At least three companies are well positioned to answer FDA Oncology chief Richard Pazdur’s call to bring Chinese PD-1/PD-L1 inhibitors to the U.S. to compete on price. Two Chinese drugmakers and one U.S. company globally...
17:54 , Jan 11, 2019 |  BC Week In Review  |  Financial News

CBT rebrands as Apollomics, raises $100M series B

CBT Pharmaceuticals Inc. has rebranded as Apollomics Inc. (Foster City, Calif.) and raised $100 million in a series B round to advance the development of its immunotherapy and targeted cancer therapy programs globally. The company...
12:51 , Jan 7, 2019 |  BC Extra  |  Financial News

CBT rebrands as Apollomics, raises $100M series B

CBT Pharmaceuticals Inc. has rebranded as Apollomics Inc. (Foster City, Calif.) and raised $100 million in a series B round to advance the development of its immunotherapy and targeted cancer therapy programs globally. The company...
20:02 , Dec 14, 2018 |  BC Week In Review  |  Company News

Strata to screen patients for Phase I of CBT's CBT-101

CBT Pharmaceuticals Inc. (Pleasanton, Calif.) and Strata Oncology Inc. (Ann Arbor, Mich.) partnered to enroll patients in a Phase I trial evaluating CBT-101 to treat c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene)-dysregulated malignancies....
21:39 , Nov 30, 2018 |  BC Week In Review  |  Company News

CBT, Bossan partner for combination trials

CBT Pharmaceuticals Inc. (Pleasanton, Calif.) gained exclusive, worldwide rights to develop and commercialize EGFR inhibitor ES-072 outside of Greater China from Zhejiang Bossan Pharmaceutical Co. Ltd. (Hangzhou, China). CBT and Bossan will jointly develop and...
22:32 , Aug 16, 2018 |  BC Extra  |  Company News

Management tracks: Achillion, Navidea

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) hired Anthony Gibney as EVP and CBO. He was managing director and co-head of the biotechnology investment banking team at Leerink Partners. Immunotherapy company Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB;...
20:10 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Autism Mouse studies suggest inhibiting MAPK could help treat autism. In a mouse model of autism, subcutaneous injection with a tool compound MAPK inhibitor decreased numbers of cortical progenitor cells and behavioral deficits and...
18:18 , Mar 30, 2018 |  BC Week In Review  |  Company News

CBT gets rights to CTLA-4 antibody

Crown Bioscience International Inc. (TPEx:6554) granted CBT Pharmaceuticals Inc. (Pleasanton, Calif.) exclusive, worldwide rights to CBT-509, a human mAb against cytotoxic T-lymphocyte associated protein 4 (CTLA-4; CTLA4; CD152). Crown is eligible for up to $47...
20:49 , Oct 13, 2017 |  BioCentury  |  Emerging Company Profile

CBT’s silk road

While several Chinese biotechs have adopted a business model in which they in-license Western assets to develop for the China market, U.S.-based CBT Pharmaceuticals Inc. is doing the reverse, sourcing innovative Chinese assets to develop...
19:08 , Sep 8, 2017 |  BioCentury  |  Finance

OrbiMed’s Asia angles

With OrbiMed’s largest ever Asia-focused healthcare fund, the firm is not only looking to write larger checks for growth companies, but is also allocating more capital toward innovative Chinese biotechs than in previous funds. On...